A prospective, multicentre study to evaluate the efficacy and safety of Ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without ribavirin in patients with genotype 1 hepatitis C and advanced liver disease in a real-world setting

Trial Profile

A prospective, multicentre study to evaluate the efficacy and safety of Ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without ribavirin in patients with genotype 1 hepatitis C and advanced liver disease in a real-world setting

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
  • Indications Hepatitis C; Liver disorders
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Acronyms Rev1tal
  • Sponsors AbbVie
  • Most Recent Events

    • 18 May 2016 New trial record
    • 17 Apr 2016 Preliminary interim analysis (n=172) presented at The International Liver Congress™ 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top